Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. - Wikidata - awgldk - TriplyDB

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

http://www.wikidata.org/entity/Q33950809

about

Heart Failure: Diagnosis, Management and Utilization Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells Proangiogenic Features of Mesenchymal Stem Cells and Their Therapeutic Applications The Evolution of the Stem Cell Theory for Heart Failure Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart?Modeling Electrophysiological Coupling and Fusion between Human Mesenchymal Stem Cells and Cardiomyocytes Stem cell therapy for CHD: towards translation Endpoints in stem cell trials in ischemic heart failure Adult Mesenchymal Stem Cells: When, Where, and How Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network Programming and reprogramming a human heart cell Stem cell imaging: from bench to bedside Transmyocardial revascularization devices: technology update Use of mesenchymal stem cells for therapy of cardiac disease Regenerative principles enrich cardiac rehabilitation practice Human iPS Cell-Derived Cardiac Tissue Sheets: a Platform for Cardiac Regeneration Cardiac Regenerative Medicine: The Potential of a New Generation of Stem Cells The winding road to regenerating the human heart Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.Cell therapy for cardiac repair--lessons from clinical trials.Tracking of stem cells in vivo for cardiovascular applications.Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.Effects of Transendocardial Stem Cell Injection on Ventricular Proarrhythmia in Patients with Ischemic Cardiomyopathy: Results from the POSEIDON and TAC-HFT Trials An innovative biologic system for photon-powered myocardium in the ischemic heart.Molecular and cellular basis of viable dysfunctional myocardium.Stem cell therapy for cardiac dysfunction Cultured human bone marrow-derived CD31(+) cells are effective for cardiac and vascular repair through enhanced angiogenic, adhesion, and anti-inflammatory effects.New vessel formation in the context of cardiomyocyte regeneration--the role and importance of an adequate perfusing vasculature.Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Cardiac regeneration using pluripotent stem cells--progression to large animal models.Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.Clinical research skills development program in cell-based regenerative medicine."Second-generation" stem cells for cardiac repair Meta-analysis of the effect of mesenchymal stem cell transplantation on vascular remodeling after carotid balloon injury in animal models.Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: a meta-analysis.

P2860

Q26745543-D1D783B3-8C65-49A6-B467-D53FBD8ACBE3 Q26746977-DDE00F2A-A6AC-45E9-B2AC-52AB8FC032A1 Q26765924-0552BBF6-BA2F-48C1-8E44-DD78D621B34D Q26769042-46ED686C-8C41-43B9-8B5D-FD51894686D0 Q26774781-C9F22BE3-6EE0-41A9-8F8B-1E0CD030F528 Q26774939-B7180839-A715-44ED-A0F5-A5B3CBD7374E Q26779602-9DB5A918-730F-4E4D-9DD5-12C18F087F47 Q26786034-6327F4D5-4773-4411-BBDB-FF4073256F9B Q26796330-0CE6D9F2-75FE-40E6-9EE7-1506725343F4 Q26798283-18FAE017-9756-4F8B-9995-3E1D5FF8F2DC Q26799905-5920A7C9-8BC8-4429-BCF5-7BDEBC6102CB Q26800196-169539A1-61B4-4770-BD94-564F7A55FB9D Q26821783-CC04B9F9-5613-4641-AC0E-6FF5DC9FA6D8 Q26823933-E6B0986F-CE47-4210-8CA2-B744B8BBDF39 Q26861615-D774D929-B32E-4BE6-A2C7-420EFB74DEAF Q26865489-0D87FBEF-A8F8-4C12-B638-52DEC11A4A81 Q27003127-9D91CF0B-BD16-4AA7-90FB-0D4FD667101E Q27022906-053AC05B-BE24-4321-BC40-7AE0242E02E1 Q28077395-A4AF1E9B-8752-4330-BC39-E5DBE8AB446E Q28079057-EDC0DE61-EC14-4145-8345-D328B9D9D980 Q28081476-145F77A8-9B5F-4E16-80CA-5E53E2FA62CF Q28082162-0618267D-113E-408F-A517-48085502337F Q30239945-57FC8200-EDFE-49C1-9023-7FD473D1AFB3 Q30359782-D98B97C8-A1C7-495B-8455-D46DE998AB12 Q30443013-7B3FDA92-36E1-4BF8-8AC1-3494C2FD5F39 Q30581265-DBBE9744-4F17-46ED-82CF-14BDE3B6708B Q33722076-8A98149E-E49F-4F9F-9873-EFC02B5F8640 Q33797866-F5B42581-8D4C-4E60-BB94-61E8271EE3CE Q33924001-66BB1F52-B0D0-416C-9866-CBF721BDCC6E Q34129904-FF36D6A8-6177-4A5D-B416-FAA298589091 Q34363654-68ECB6FE-DAC9-4D62-BDA9-751A24A86A37 Q34422460-43A8A2B8-0CF1-4151-9FA3-E25B6575BA44 Q34441749-44F64273-CCD6-4C32-A172-1A4369D3E725 Q34617472-460B0B1B-6E21-429A-A2F3-F3880CE959E9 Q34661275-E9309DBB-07C0-41F9-A30D-5FAC47B732FA Q34807168-1B201D78-1855-4F94-B4F8-FB55052DADBF Q35001367-3CB20682-93DF-4681-9D34-1807C191F105 Q35205665-9D750430-0A2F-4316-B040-3E1636B7C352 Q35219587-C6704339-8DFB-4810-9CB4-DC8F2AB12D6B Q35290282-96489F59-8F17-4A24-8E38-4B552390FF95

P2860

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

http://www.wikidata.org/entity/Q33950809

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@ast

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@en

type

label

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@ast

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@en

prefLabel

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@ast

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@en

P1433

Q33950809-3EBDA151-7D28-43B5-9EFC-9BF270D5BF78

P1476

Q33950809-7FDC9C43-E31C-43BB-892E-8CC3C1748AE2

P2093

Q33950809-00E76778-C6CE-40AF-8035-0F4C40C7D2A7

Q33950809-06C043D8-F54F-4D77-8D2A-0FE87234A354

Q33950809-074A11C7-D8D4-424D-BA29-E7BBC391ACCF

Q33950809-0C746D97-7264-47DE-BA85-2488EEEB04B6

Q33950809-154FF6DE-1AC2-4224-902F-9B4F5B8C5A75

Q33950809-160BD17E-BC39-417F-B4D5-8209E2654310

Q33950809-20F6FFCC-36F9-4854-A571-E64E5554F6DC

Q33950809-2F5E99B2-5398-4304-8822-8D69D0CD1A02

Q33950809-2FE9B8DD-6651-4194-ABC3-5EC0C955D829

Q33950809-3717726D-DF15-41FD-881B-425D4D61DCE7

P2860

Q33950809-0053ADC7-B25B-4398-9BB9-9FD96F85D419

Q33950809-07066C8A-732D-47B0-81C1-23825E4C5AF3

Q33950809-0735E48C-8A92-46F6-82E6-050CC4AC4E62

Q33950809-07AACE93-BA65-450F-999C-3D5FC1317E59

Q33950809-132BDF38-D2F8-4A91-BF84-631FC9E807E4

Q33950809-180D7A68-3E45-4EE0-8DA6-58EF13F81C66

Q33950809-1F3242AE-0CA9-4575-903F-FC2A7051CA2C

Q33950809-2DC5E2E1-5B43-492B-ACD7-9AEA92371BEC

Q33950809-31702D41-86FC-4BD8-AE37-DB79E3D2C50B

Q33950809-3C1FAE96-35BA-4DE9-BDA2-A740C9BA743B

P304

Q33950809-9978E519-EF40-4384-A156-2DDB4BFDD7D1

P31

Q33950809-4E958315-4A63-421C-B67A-B673300EEBD3

P356

Q33950809-9CEAC112-5B4A-4C0B-A562-2F35ED16C39C

P407

Q33950809-E2B493B6-A806-4A9A-9D9E-54AD8173CB70

P433

Q33950809-55AF8BD2-0DD6-409E-ABF1-6447880441F6

P478

Q33950809-240B4364-253A-47C7-8A22-0C3A5F53A2EA

P577

Q33950809-DA2871FD-1152-460F-9DE9-BB3B3007CEF3

P5875

Q33950809-AE514998-272E-48EE-98AC-453CD9320DBC

P698

Q33950809-E9A88D60-0006-4973-B5A4-7C24C3CC7AD1

P932

Q33950809-7246568A-F676-486F-B08A-9DA8BB119AA7

P356

JAMA.2013.282909

P1433

Journal of the American Medical Association

P1476

Transendocardial mesenchymal s ...... the TAC-HFT randomized trial.

@en

P2093

Adam Mendizabal

http://www.w3.org/2001/XMLSchema#string

Adam R Williams

http://www.w3.org/2001/XMLSchema#string

Alan W Heldman

http://www.w3.org/2001/XMLSchema#string

Barry H Trachtenberg

http://www.w3.org/2001/XMLSchema#string

Behzad Oskouei

http://www.w3.org/2001/XMLSchema#string

Cheryl Wong Po Foo

http://www.w3.org/2001/XMLSchema#string

Cindy Delgado

http://www.w3.org/2001/XMLSchema#string

Darcy L DiFede

http://www.w3.org/2001/XMLSchema#string

Didier Rouy

http://www.w3.org/2001/XMLSchema#string

Eduard Ghersin

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac CT: Imaging of and Through Cardiac Devices.

Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease

Multilineage potential of adult human mesenchymal stem cells

Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial

Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation

Transcoronary transplantation of progenitor cells after myocardial infarction.

Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemic myocardium

Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.

Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage.

P304

62-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.282909

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

311

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258701240

http://www.w3.org/2001/XMLSchema#string

P698

24247587

http://www.w3.org/2001/XMLSchema#string

P932

4111133

http://www.w3.org/2001/XMLSchema#string